GSK, Zymeworks expand partnership for bispecific antibody development
Category: #health  By Nikita Chaurasia  Date: 2019-05-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

GSK, Zymeworks expand partnership for bispecific antibody development

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases

Zymeworks Inc, a clinical-stage biopharmaceutical company, has recently announced that GSK has extended its 2016 licensing and partnership agreement with Zymeworks for R&D and commercialization of bispecific antibodies for several types of diseases.

Apparently, under the extended agreement, GSK would be able to access to exclusive heavy-light chain pairing technology of Zymeworks as well as part of its branded Azymetric™ platform. The Azymetric platform from Zymeworks allows the development of bispecific drugs and multifunctional therapeutics while maintaining the features of naturally occurring human antibodies.

According to President and CEO of Zymeworks, Ali Tehrani, Ph.D., as part of this extended agreement GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs for the treatment of communicable diseases. It also highlights the efficacy of the company’s platform beyond traditional indications such as inflammatory disease and oncology.

Sources familiar with the matter mentioned that under the updated terms of the extended agreement, GSK will have the option to commercialize and develop bispecific drugs across different disease areas and Zymeworks would be eligible for receiving increased preclinical, research & development and commercial milestone payments.

Reportedly, once all six programs are commercialized and developed then the new potential value of the partnership would be around US$1.1 billion.  In addition, Zymeworks is entitled to receive augmented tiered royalties on global sales.

The Azymetric platform seemingly allows monospecific antibodies to convert into bispecific antibodies, providing the antibodies the capability to concurrently bind two different targets. Azymetric bispecific technology allows the development of multifunctional therapeutics that can restrict various signaling pathways, increase tumor-specific targeting, recruit immune cells to tumors, and enhance receptor clustering degradation.

These characteristics are proposed to improve efficacy while reducing the potential for drug resistance and toxicities, sources added. The Azymetric bispecifics have been engineered for retaining the required drug-like abilities of naturally occurring antibodies, including high stability, long half-life, and low immunogenicity.

 

Source Credit: https://www.businesswire.com/news/home/20190516005061/en/Zymeworks-GSK-Expand-2016-Azymetric%E2%84%A2-Bispecific-Agreement

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Mallinckrodt states positive results of Terlipressin in HRS-1 patients
Mallinckrodt states positive results of Terlipressin in HRS-1 patients
By Nikita Chaurasia

The company announced positive results from its Phase 3 CONFIRM trial of terlipressin in Hepatorenal Syndrome Type 1. The study verified HRS-1 reversal along with other 3 components-renal function enhancement, escaping dialysis, and short-term sur...

Rhodes Group & BCBSNM team up to improve patient outcome in New Mexico
Rhodes Group & BCBSNM team up to improve patient outcome in New Mexico
By Nikita Chaurasia

The collaboration aims to enhance patient outcomes within the New Mexico Centennial Care. BCBSNM is currently holds the accolade of being the foremost performer in Postpartum and Prenatal care. Rhodes Group (Rhodes), a Albuquerque-based TriCore...

London’s health startup Thriva bags £6M in Series A funding round
London’s health startup Thriva bags £6M in Series A funding round
By Nikita Chaurasia

The company will use this funding to build towards its ambitious vision of offering optimal healthcare to potential customers. Thriva, a UK-based health service startup, has reportedly managed to secure £6 million through a Series A funding ro...